Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has issued new draft guidances related to its accelerated approval pathway. These guidances may have implications for drug companies. The details and potential effects of the new draft guidances are being considered.